Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Physical isolation of tumor associated ctDNA fragments for novel prostate cancer liquid biopsy

Wednesday, March 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The presentation titled 'Physical isolation of tumor associated ctDNA fragments for novel prostate cancer liquid biopsy' was delivered at the 34th International Prostate Cancer Update. It emphasizes a novel method for isolating ctDNA, which may enhance the accuracy of liquid biopsies in prostate cancer detection. The findings could have significant implications for cancer diagnostics.
Price reaction · baseline $17.4 (2024-03-05 close) · hit pre-market · 3 other VNRX headline(s) in the window, move may be shared
day 0 close
+14.3%
day 1
+13.8%
day 3 · peak
+21.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation highlights innovative approach to prostate cancer detection.
  • Focus on ctDNA fragments could improve liquid biopsy accuracy.
  • Potential for enhanced prognostic value in cancer diagnostics.

Full Press Release Details

Presentation titled: Physical isolation of tumor associated ctDNA fragments for novel prostate cancer liquid biopsy
Presented at: 34th International Prostate Cancer Update
Pamart et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the presentation?

The presentation focused on isolating tumor-associated ctDNA fragments for prostate cancer liquid biopsy.

Where was the presentation delivered?

It was presented at the 34th International Prostate Cancer Update.

What is ctDNA?

ctDNA refers to circulating tumor DNA, which can provide insights into cancer presence and progression.

What are the potential benefits of this method?

This method could improve the accuracy of liquid biopsies in detecting prostate cancer.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare ctDNA prostate cancer liquid biopsy cancer diagnostics
Last updated: Mar 6, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk